ID   KPCD2_HUMAN             Reviewed;         878 AA.
AC   Q9BZL6; Q8TB08; Q9P0T6; Q9Y3X8;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 2.
DT   05-OCT-2010, entry version 110.
DE   RecName: Full=Serine/threonine-protein kinase D2;
DE            EC=2.7.11.13;
DE   AltName: Full=nPKC-D2;
GN   Name=PRKD2; Synonyms=PKD2; ORFNames=HSPC187;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION AT SER-876, AND VARIANT
RP   ALA-835.
RC   TISSUE=Pancreas;
RX   PubMed=11062248; DOI=10.1074/jbc.M008719200;
RA   Sturany S., Van Lint J., Mueller F., Wilda M., Hameister H.,
RA   Hoecker M., Brey A., Gern U., Vandenheede J., Gress T., Adler G.,
RA   Seufferlein T.;
RT   "Molecular cloning and characterization of the human protein kinase
RT   D2. A novel member of the protein kinase d family of serine threonine
RT   kinases.";
RL   J. Biol. Chem. 276:3310-3318(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 337-878, AND VARIANT
RP   ALA-835.
RC   TISSUE=Uterus;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 574-878, AND VARIANT
RP   ALA-835.
RC   TISSUE=Umbilical cord blood;
RX   MEDLINE=20499367; PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197 AND SER-198, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Colon adenocarcinoma;
RX   PubMed=16083285; DOI=10.1021/pr050048h;
RA   Kim J.-E., Tannenbaum S.R., White F.M.;
RT   "Global phosphoproteome of HT-29 human colon adenocarcinoma cells.";
RL   J. Proteome Res. 4:1339-1346(2005).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-214 AND
RP   SER-710, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [8]
RP   PHORBOL-ESTER BINDING, AND MUTAGENESIS OF PRO-275.
RX   PubMed=18076381; DOI=10.1042/BJ20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual
RT   C1 domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-200, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-214; SER-375;
RP   SER-396; SER-518; SER-706; SER-710 AND SER-876, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-197; SER-200; SER-203;
RP   SER-206; SER-214 AND SER-710, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-189; SER-197; SER-198;
RP   THR-199; SER-200; SER-206; SER-214; SER-225; THR-227; SER-236;
RP   SER-237; SER-238; SER-338; SER-353; SER-355; SER-362; SER-374;
RP   SER-375; SER-518; SER-706; SER-710; TYR-717 AND SER-876, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-206 AND SER-710, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   STRUCTURE BY NMR OF 395-509.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PH domain of protein kinase C, D2 type from
RT   human.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-324; VAL-496; GLY-604; ARG-773;
RP   GLU-848 AND GLU-870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Converts transient diacylglycerol (DAG) signals into
CC       prolonged physiological effects, downstream of PKC. Involved in
CC       resistance to oxidative stress (By similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR: Magnesium (By similarity).
CC   -!- ENZYME REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domains bind DAG, mediating translocation to
CC       membranes. Autophosphorylation of Ser-710 and phosphorylation of
CC       Ser-706 by PKC relieves auto-inhibition by the PH domain (By
CC       similarity).
CC   -!- SUBCELLULAR LOCATION: Cytoplasm (By similarity). Membrane (By
CC       similarity). Note=Translocation to the cell membrane is required
CC       for kinase activation (By similarity).
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- PTM: Phosphorylation of Ser-876 correlates with the activation
CC       status of the kinase.
CC   -!- PTM: Ser-706 is probably phosphorylated by PKC.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. PKD subfamily.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 2 phorbol-ester/DAG-type zinc fingers.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF36107.1; Type=Frameshift; Positions=604, 606, 738, 744, 755, 758, 833, 854;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF309082; AAK01149.1; -; mRNA.
DR   EMBL; AC008635; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC093503; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL050147; CAB43292.1; -; mRNA.
DR   EMBL; AF151021; AAF36107.1; ALT_FRAME; mRNA.
DR   IPI; IPI00941257; -.
DR   PIR; T08777; T08777.
DR   RefSeq; NP_001073349.1; -.
DR   RefSeq; NP_001073350.1; -.
DR   RefSeq; NP_001073351.1; -.
DR   RefSeq; NP_057541.2; -.
DR   UniGene; Hs.466987; -.
DR   PDB; 2COA; NMR; -; A=398-509.
DR   PDB; 3BGM; X-ray; 1.60 A; C=526-534.
DR   PDBsum; 2COA; -.
DR   PDBsum; 3BGM; -.
DR   ProteinModelPortal; Q9BZL6; -.
DR   SMR; Q9BZL6; 130-192, 245-318, 549-811.
DR   MINT; MINT-1179710; -.
DR   STRING; Q9BZL6; -.
DR   PhosphoSite; Q9BZL6; -.
DR   PRIDE; Q9BZL6; -.
DR   Ensembl; ENST00000291281; ENSP00000291281; ENSG00000105287.
DR   Ensembl; ENST00000433867; ENSP00000393978; ENSG00000105287.
DR   Ensembl; ENST00000454760; ENSP00000414761; ENSG00000105287.
DR   GeneID; 25865; -.
DR   KEGG; hsa:25865; -.
DR   UCSC; uc002pfh.1; human.
DR   CTD; 25865; -.
DR   GeneCards; GC19M047177; -.
DR   HGNC; HGNC:17293; PRKD2.
DR   HPA; HPA021490; -.
DR   MIM; 607074; gene.
DR   PharmGKB; PA134903505; -.
DR   HOVERGEN; HBG003564; -.
DR   InParanoid; Q9BZL6; -.
DR   BRENDA; 2.7.11.13; 247.
DR   NextBio; 47239; -.
DR   ArrayExpress; Q9BZL6; -.
DR   Bgee; Q9BZL6; -.
DR   CleanEx; HS_PKD2; -.
DR   CleanEx; HS_PRKD2; -.
DR   Genevestigator; Q9BZL6; -.
DR   GermOnline; ENSG00000105287; Homo sapiens.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:EC.
DR   GO; GO:0023034; P:intracellular signaling pathway; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; NAS:UniProtKB.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 1.
DR   PANTHER; PTHR22968; PKC_mu_like; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Cytoplasm; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Repeat; Serine/threonine-protein kinase;
KW   Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    878       Serine/threonine-protein kinase D2.
FT                                /FTId=PRO_0000055716.
FT   DOMAIN      397    509       PH.
FT   DOMAIN      551    807       Protein kinase.
FT   ZN_FING     138    188       Phorbol-ester/DAG-type 1.
FT   ZN_FING     264    314       Phorbol-ester/DAG-type 2.
FT   NP_BIND     557    565       ATP (By similarity).
FT   ACT_SITE    674    674       Proton acceptor (By similarity).
FT   BINDING     580    580       ATP (By similarity).
FT   MOD_RES     189    189       Phosphoserine.
FT   MOD_RES     197    197       Phosphoserine.
FT   MOD_RES     198    198       Phosphoserine.
FT   MOD_RES     199    199       Phosphothreonine.
FT   MOD_RES     200    200       Phosphoserine.
FT   MOD_RES     203    203       Phosphoserine.
FT   MOD_RES     206    206       Phosphoserine.
FT   MOD_RES     212    212       Phosphoserine (By similarity).
FT   MOD_RES     214    214       Phosphoserine.
FT   MOD_RES     225    225       Phosphoserine.
FT   MOD_RES     227    227       Phosphothreonine.
FT   MOD_RES     236    236       Phosphoserine.
FT   MOD_RES     237    237       Phosphoserine.
FT   MOD_RES     238    238       Phosphoserine.
FT   MOD_RES     338    338       Phosphoserine.
FT   MOD_RES     353    353       Phosphoserine.
FT   MOD_RES     355    355       Phosphoserine.
FT   MOD_RES     362    362       Phosphoserine.
FT   MOD_RES     374    374       Phosphoserine.
FT   MOD_RES     375    375       Phosphoserine.
FT   MOD_RES     396    396       Phosphoserine.
FT   MOD_RES     518    518       Phosphoserine.
FT   MOD_RES     706    706       Phosphoserine.
FT   MOD_RES     710    710       Phosphoserine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     717    717       Phosphotyrosine.
FT   MOD_RES     876    876       Phosphoserine; by autocatalysis.
FT   VARIANT     324    324       V -> M (in dbSNP:rs45455991).
FT                                /FTId=VAR_042330.
FT   VARIANT     496    496       A -> V (in dbSNP:rs55716765).
FT                                /FTId=VAR_042331.
FT   VARIANT     604    604       S -> G (in dbSNP:rs34325043).
FT                                /FTId=VAR_042332.
FT   VARIANT     773    773       W -> R (in dbSNP:rs55933311).
FT                                /FTId=VAR_042333.
FT   VARIANT     835    835       V -> A (in dbSNP:rs314665).
FT                                /FTId=VAR_061531.
FT   VARIANT     848    848       G -> E (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042334.
FT   VARIANT     870    870       G -> E (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042335.
FT   MUTAGEN     275    275       P->G: Increase in ability to bind phorbol
FT                                ester, slight increase in ability to bind
FT                                DAG.
FT   CONFLICT    790    790       V -> L (in Ref. 4; AAF36107).
FT   STRAND      399    406
FT   STRAND      409    411
FT   STRAND      415    421
FT   STRAND      423    433
FT   STRAND      438    442
FT   TURN        443    445
FT   STRAND      448    452
FT   STRAND      456    458
FT   STRAND      465    470
FT   STRAND      486    488
FT   HELIX       495    507
SQ   SEQUENCE   878 AA;  96750 MW;  8BAB45FB5B1718E7 CRC64;
     MATAPSYPAG LPGSPGPGSP PPPGGLELQS PPPLLPQIPA PGSGVSFHIQ IGLTREFVLL
     PAASELAHVK QLACSIVDQK FPECGFYGLY DKILLFKHDP TSANLLQLVR SSGDIQEGDL
     VEVVLSASAT FEDFQIRPHA LTVHSYRAPA FCDHCGEMLF GLVRQGLKCD GCGLNYHKRC
     AFSIPNNCSG ARKRRLSSTS LASGHSVRLG TSESLPCTAE ELSRSTTELL PRRPPSSSSS
     SSASSYTGRP IELDKMLLSK VKVPHTFLIH SYTRPTVCQA CKKLLKGLFR QGLQCKDCKF
     NCHKRCATRV PNDCLGEALI NGDVPMEEAT DFSEADKSAL MDESEDSGVI PGSHSENALH
     ASEEEEGEGG KAQSSLGYIP LMRVVQSVRH TTRKSSTTLR EGWVVHYSNK DTLRKRHYWR
     LDCKCITLFQ NNTTNRYYKE IPLSEILTVE SAQNFSLVPP GTNPHCFEIV TANATYFVGE
     MPGGTPGGPS GQGAEAARGW ETAIRQALMP VILQDAPSAP GHAPHRQASL SISVSNSQIQ
     ENVDIATVYQ IFPDEVLGSG QFGVVYGGKH RKTGRDVAVK VIDKLRFPTK QESQLRNEVA
     ILQSLRHPGI VNLECMFETP EKVFVVMEKL HGDMLEMILS SEKGRLPERL TKFLITQILV
     ALRHLHFKNI VHCDLKPENV LLASADPFPQ VKLCDFGFAR IIGEKSFRRS VVGTPAYLAP
     EVLLNQGYNR SLDMWSVGVI MYVSLSGTFP FNEDEDINDQ IQNAAFMYPA SPWSHISAGA
     IDLINNLLQV KMRKRYSVDK SLSHPWLQEY QTWLDLRELE GKMGERYITH ESDDVRWEQF
     AAEHPLPGSG LPTDRDLGGA CPPQDHDMQG LAERISVL
//
